Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
- Investor presentation at H.C. Wainwright conference and upcoming scientific conferences could generate positive interest and potential investment opportunities for Anebulo Pharmaceuticals.
- None.
Details for the upcoming conference presentations are as follows:
H.C. Wainwright 25th Annual Global Investment Conference (
- The Company presentation will be available on-demand on September 11, 2023, at 7 a.m. ET through the conference website.
- Simon Allen, Chief Executive Officer of Anebulo, will be available in person for one-on-one investor meetings.
North American Congress on Clinical Toxicology (
- Oral Presentation Title: Randomized Controlled Trial of ANEB-001 as an Antidote for Acute Cannabinoid Intoxication in Healthy Adults
- Presenter: Andrew Monte, MD, Ph.D.
- Date: Friday, September 29, 2023, from 1 p.m. to 3 p.m. ET
American Congress of Emergency Physicians (
- Poster Presentation Title: Prediction of a Therapeutically Active Dose of the Cannabinoid Type 1 Receptor Antagonist ANEB-001 For Reversal of Acute Cannabis Intoxication Using a Pharmacokinetic / Pharmacodynamic Model
- Presenter: Linda Klumpers, Ph.D.
- Date: Monday, October 9, 2023, at 10:30 a.m. ET
- Location: Room 108AB
- Oral Presentation Title: Randomized Controlled Trial of ANEB-001 as an Antidote for Acute Cannabinoid Intoxication in Healthy Adults
- Presenter: Andrew Monte, MD, Ph.D.
- Date: Tuesday, October 10, 2023, at 3:30 p.m. ET
- Location: Room 105AB
About the Phase 2 study of ANEB-001
Parts A and B of the Phase 2 study were previously conducted in
About ANEB-001
Our lead product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, under development to address the unmet medical need for a specific antidote for ACI. ANEB-001 is an orally bioavailable, readily absorbed treatment candidate that we anticipate will rapidly reverse key symptoms of ACI. ANEB-001 is protected by one issued patent and rights to one patent application covering various methods of use of the compound and delivery systems. We began a Phase 2 proof-of-concept trial for ANEB-001 in December 2021 in
About Acute Cannabinoid Intoxication
Symptoms of ACI can include increased somnolence, impaired cognition and perception, disorientation, anxiety, and acute psychosis. A diagnosis of cannabinoid intoxication includes a recent history of cannabinoid use, and clinically considerable behavioral or psychological changes, such as anxiety, panic attacks, euphoria, impaired judgment and motor skills, and elevated heart rate, which have taken place since cannabinoid exposure.
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder. Its lead product candidate, ANEB-001, has completed dosing in a Phase 2 clinical trial (www.clinicaltrials.gov/ct2/show/NCT05282797) evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication. ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1). For further information about Anebulo, please visit www.anebulo.com.
About The
The
Forward Looking Statements
Statements contained in this press release that are not statements of historical fact are forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, these forward-looking statements can be identified by words such as "anticipate," "designed," "expect," "may," "will," "should" and other comparable terms. Forward-looking statements include statements regarding Anebulo's intentions, beliefs, projections, outlook, analyses or current expectations regarding: the potential for a single well-controlled study of ANEB-001 in ACI patients presenting to the emergency department combined with a larger THC challenge study in volunteers to provide substantial evidence to support a new drug application; the path forward for designing and executing Phase 3 trials with ANEB-001 and whether it is viable and our plans for pursuing Phase 3 development in an efficient matter; the expected timing for results from the open-label Part C extension of our Phase 2 clinical trial; the timing of future updates on the advancement of ANEB-001; future results that may be implied by prior results; the potential for ANEB-001 to address an unmet medical need for a specific antidote for ACI; and Anebulo's expectation that ANEB-001 will rapidly reverse key symptoms of ACI. You are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to a number of risks, uncertainties and assumptions, including, but not limited to: initial and interim results from clinical studies are not necessarily indicative of results that may be observed in the future; the ability to obtain regulatory approval; the Type B meeting minutes should not be relied on as an indication that ANEB-001 will ultimately be approved; the timing and success of clinical trials and potential safety and other complications thereof; any negative effects on the Company's business and product development plans caused by or associated with health crises or geopolitical issues; and Anebulo's need for additional capital. These and other risks are described under the "Risk Factors" heading of Anebulo's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, as filed with the SEC on May 11, 2023. All forward-looking statements made in this press release speak only as of the date of this press release and are based on management's assumptions and estimates as of such date. Except as required by law, Anebulo undertakes no obligation to update or revise forward-looking statements to reflect new information, future events, changed conditions or otherwise after the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230830331645/en/
Media Contact
Ignacio Guerrero-Ros, Ph.D.
Russo Partners
(646) 942-5604
ignacio.guerrero-ros@russopartnersllc.com
Investor Relations
Adanna Alexander, Ph.D. or Harrison Seidner, Ph.D.
(646) 942-5603
(646) 942-5599
Adanna@RussoPR.com
Harrison.seidner@russopartnersllc.com
Anebulo Pharmaceuticals, Inc.
Sandra Gardiner
Acting Chief Financial Officer
(512) 598-0931
Sandra@anebulo.com
Welcome0918
Source: Anebulo Pharmaceuticals, Inc.